Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2

European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
Said FarschtschiVictor-Felix Mautner

Abstract

Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome associated with vestibular schwannomas and other benign tumors of the central nervous system. Bevacizumab is used for treatment of progressive vestibular schwannomas, with the intent to reduce tumor size or preserve/improve hearing. Prolonged treatment can cause side effects such as hypertension and proteinuria, which can be cause for discontinuation of therapy. We report on 3 patients who were treated with bevacizumab for 66-76 months, with dose reductions that minimized side effects while sustaining the clinical effect of the antiangiogenic therapy. After dose reduction from 5 mg/kg bi- or tri-weekly to 2.5 mg bi- or tri-weekly, all patients appeared clinically stable and radiographic and audiologic follow-up showed sustained response. In conclusion, in some NF2 patients, dose reduction of bevacizumab seems to be an effective option for managing side effects.

References

Jul 2, 1997·JAMA : the Journal of the American Medical Association·D H GutmannD Viskochil
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S GordonD Adelman
Feb 9, 2005·Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·D Gareth R EvansRichard Ramsden
Jul 10, 2009·The New England Journal of Medicine·Scott R PlotkinEmmanuelle di Tomaso
Sep 24, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V-F MautnerC Bokemeyer
Jul 19, 2012·Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·Scott R PlotkinFred G Barker
Jan 18, 2014·Journal of Neurological Surgery. Part B, Skull Base·Ammar H HawasliMichael R Chicoine
Apr 9, 2014·Cancer Chemotherapy and Pharmacology·Katherine M SlusarzScott R Plotkin
Sep 27, 2014·American Journal of Medical Genetics. Part a·Scott R PlotkinAlison C Lloyd
Nov 26, 2014·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Mikkel Christian AlaninKenneth Francis Hofland

❮ Previous
Next ❯

Citations

Dec 27, 2015·Seminars in Pediatric Neurology·Martino RuggieriDafydd Gareth Evans
Apr 4, 2017·Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·S K W LloydD G Evans
Jan 7, 2020·Neurologia Medico-chirurgica·Masazumi FujiiKiyoshi Saito
Apr 22, 2017·Oncotarget·Alejandra M PetrilliCristina Fernández-Valle
Nov 1, 2016·Journal of Neuro-oncology·Katrina A MorrisUNKNOWN UK NF2 research group
Jan 16, 2021·Drug Design, Development and Therapy·Jianfei LongBin Wang
Jun 15, 2021·Otolaryngologic Clinics of North America·Scott Raskin, Miriam Bornhorst

❮ Previous
Next ❯

Related Concepts

Related Feeds

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.

Related Papers

Cancer Chemotherapy and Pharmacology
Katherine M SlusarzScott R Plotkin
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
Scott R PlotkinFred G Barker
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
James R TysomePatrick R Axon
The New England Journal of Medicine
Scott R PlotkinEmmanuelle di Tomaso
© 2021 Meta ULC. All rights reserved